Immunotherapy after surgery for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving immunotherapy after surgery can help prevent cancer from returning in patients with esophageal squamous cell carcinoma. It is for people who have already received chemotherapy and immunotherapy before surgery and had surgery to remove the cancer, but still had some cancer cells found in the removed tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with squamous cell carcinoma of the esophagus.
- You have received chemotherapy and immunotherapy before surgery, and had surgery to remove all visible cancer.
- After surgery, lab tests showed that some cancer cells were still present in the removed tissue (stage ypT1 or higher, or ypN1 or higher).
- You are in good general health and your major organs (heart, lungs, liver, kidneys) are working normally.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This trial compares the current standard treatment (chemotherapy and radiation) with a newer approach that combines chemotherapy and immunotherapy before surgery for esophageal cancer. Participation may help determine if this new combination is more effective for you.
This trial tests a treatment plan that combines immunotherapy with chemotherapy before possible endoscopic surgery. It is for people with a specific type of esophageal cancer that has not been treated before and is either potentially removable or not suitable for standard surgery.
This study tests a new combination approach before surgery for esophageal cancer. You would receive a short course of radiation together with an immunotherapy drug called serplulimab and standard chemotherapy, to see if it helps shrink the tumor and improve outcomes.
This trial tests a combination of short-course radiation, an immunotherapy drug called tislelizumab, and chemotherapy before surgery for esophageal cancer that has spread to nearby lymph nodes but hasn't spread to distant organs. The goal is to shrink the tumor before surgery and improve outcomes.
This trial is for people with advanced esophageal cancer that hasn't spread far. After initial treatment with chemotherapy, immunotherapy, and radiation, you'll either get toripalimab or just be watched to see which approach works better.
Hear when a new Esophageal Squamous Cell Carcinoma (ESCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.